Table 1 Baseline characteristics
HFA-PEFF score tertiles | Low (n = 79) | Intermediate (n = 107) | High (n = 34) | p-value |
|---|---|---|---|---|
Demographics | ||||
 Female gender, n (%) | 59(74.7%) | 68(63.6%) | 23(67.6%) | 0.272 |
 Age, median (IQR), years | 50(41–59) | 55(48–63) | 66(50–68) | 0.001 |
 BMI > 24 kg/m2, n (%) | 15(30.0%) | 38(42.2%) | 39(57.6%) | 0.044 |
 Duration, median (IQR), months | 5(2–12) | 6(3–12) | 8(4–15) | 0.497 |
Clinical manifestations, n (%) | ||||
 Fever | 23(29.1%) | 54(50.5%) | 10(29.4%) | 0.006 |
 Rash | 49(62.0%) | 70(65.4%) | 20(58.8%) | 0.758 |
 Muscle weakness | 39(49.4%) | 53(49.5%) | 17(50.0%) | 0.998 |
 Arthralgia | 36(45.6%) | 44(41.1%) | 7(20.6%) | 0.040 |
 Dysphagia | 6(7.6%) | 9(8.4%) | 4(11.8%) | 0.764 |
 Dyspnea | 30(38.0%) | 53(49.5%) | 22(64.7%) | 0.029 |
 Palpitation | 7(8.9%) | 32(29.9%) | 13(38.2%) |  < 0.001 |
 Interstitial lung disease | 53(67.1%) | 81(75.7%) | 30(88.2%) | 0.056 |
Comorbidities, n (%) | ||||
 Hypertension | 8(10.1%) | 25(23.4%) | 14(41.2%) | 0.001 |
 Diabetes mellitus | 10(12.7%) | 19(17.8%) | 15(44.1%) |  < 0.001 |
 Malignancies | 6(7.6%) | 9(8.4%) | 4(11.8%) | 0.764 |
 Renal dysfunction a | 0(0.0%) | 1(1.0%) | 0(0.0%) | 0.567 |
Laboratory values, median (IQR) | ||||
 CK, IU/L | 99(41–408) | 105(51–397) | 80(54–495) | 0.979 |
 CK-MB, ng/mL | 2.6(0.7–8.4) | 2.3(1.1–12.3) | 3.5(1.5–14.0) | 0.206 |
 LDH, IU/L | 245(174–370) | 296(220–431) | 313(225–497) | 0.021 |
 cTnI, ng/mL | 0.01(0.01–0.01) | 0.01(0.01–0.03) | 0.03(0.01–0.05) | 0.003 |
 NT-proBNP, pg/mL | 68.1(45.2–100.4) | 144.3(61.9–298.4) | 413.6(212.6–690.2) |  < 0.001 |
Core set measures, median (IQR) | ||||
 PhGA | 2.0(1.0–2.5) | 3.0(2.0–3.5) | 4.5(3.5–5.1) |  < 0.001 |
 PGA | 2.0(1.0–3.5) | 3.0(2.0–4.5) | 4.5(3.0–6.0) |  < 0.001 |
 MMT-8 | 80(70–80) | 80(70–80) | 78(74–80) | 0.977 |
 HAQ | 0.2(0.0–0.4) | 0.2(0.0–0.7) | 0.3(0.2–1.2) | 0.058 |
 MYOACT | 3(2–4) | 3(2–4) | 4(3–4) | 0.001 |